Sino Biopharmaceutical co-led the oncology treatment developer's latest round, in which it raised over $91m in funding.

The neurodegenerative disease therapy developer has set a $100m placeholder target for an offering following $140m in funding from investors including Amgen and Pivotal BioVentures.

Bringing together researchers from Italy and the US, Chroma Medicine has emerged out of stealth with series A financing led by Cormorant Asset Management.

Vifor Pharma is snapping up Lundbeck and Baxter-backed vascular drug developer Sanifit for at least $231m while solar project developer SUN Energy closed $25m in funding at a $200m valuation.

Nationwide Ventures participated in a round for the Medicare brokerage made up of $35m in equity financing and a $100m credit facility.

Sino Biopharmaceutical co-led the oncology treatment developer's latest round, in which it raised over $91m in funding.

Autonomous driving technology developer MaxiEye bagged nearly $50m in a Desay-led round while software testing technology producer Mabl raised $40m from investors including GV and Presidio Ventures.

Cancer research software provider Owkin received the funding as part of a strategic collaboration partnership which will involve it working with Sanofi on potential treatments.

Labcorp backed a debt and equity round for the cancer diagnostics technology developer as it advances its screening platform torwards commercialisation.

Koch Disruptive Technologies helped molecular diagnostics system developer Sense Biodetection expand its latest round to $65m while Hilti bought portfolio company Fieldwire for $300m.